Dynamic Neural Mechanisms of Brexanolone-induced Antidepressant Effects in Postpartum Depression

CompletedOBSERVATIONAL
Enrollment

10

Participants

Timeline

Start Date

August 5, 2022

Primary Completion Date

November 15, 2023

Study Completion Date

November 15, 2023

Conditions
Postpartum Depression
Interventions
DRUG

Brexanolone

Enrolled subjects will receive a 60-hour infusion of Brexanolone (BRX) according to FDA approved protocol for administration. A programmable peristaltic infusion pump will be used to ensure accurate delivery.

Trial Locations (1)

27599

University of North Carolina, Chapel Hill

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Baszucki Brain Research Fund

OTHER

collaborator

Sage Therapeutics

INDUSTRY

lead

University of North Carolina, Chapel Hill

OTHER

NCT05543746 - Dynamic Neural Mechanisms of Brexanolone-induced Antidepressant Effects in Postpartum Depression | Biotech Hunter | Biotech Hunter